Panelists discuss how both TAR-200 and UGN-102/103 represent innovative approaches to intravesical drug delivery for bladder conditions. TAR-200 uses a novel silicone-based system designed for ...

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune ...

"For the MIRAGE trial specifically, we're going to continue following patients and we'll look at [data at] 5 years as well," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares future ...

UGN-101 (Jelmyto) shows a median response duration of nearly four years in low-grade UTUC patients achieving complete response. The FDA approved UGN-101 in April 2020 based on favorable phase 3 ...

Mevrometostat combined with enzalutamide improved median rPFS to 14.3 months versus 6.2 months with enzalutamide alone in mCRPC patients. The combination therapy showed a higher objective response ...

Diverse biomarkers, including PSA, BRCA mutations, PSMA, and AR-V7, guide treatment decisions in advanced prostate cancer management. Emerging biomarkers like ctDNA and PTEN loss offer predictive and ...

EP: 19.Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC ...

"I think targeting things that make communities more vulnerable would be reasonable things to target to try and affect disease practices," says William Furuyama, MD. In this video, William Furuyama, ...

"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD. In this video, Matthew J. Mutter, MD, highlights ...

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine. In this video, from the 2025 Desai Sethi Urology Institute Urology on the Beach meeting, Dayna R. Smerina ...

Precision-based care is enhancing urologic diagnostics, reducing unnecessary interventions, and improving treatment personalization, particularly in prostate cancer. Workforce shortages and an aging ...

Ibex Prostate Detect uses AI to analyze prostate biopsy images, generating heatmaps and alerts to assist pathologists in identifying missed tumors. The software achieved a 99.6% positive predictive ...